Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CLINIMIX E 2.75/5 is a combination of amino acids, electrolytes, and dextrose used for parenteral nutrition. The amino acids provide substrates for protein synthesis, dextrose supplies caloric energy, and electrolytes maintain acid-base and fluid balance. Calcium is included for bone health and neuromuscular function.
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
Parenteral nutrition for patients with or without electrolyte abnormalities who require intravenous feeding,Peripheral or central venous nutrition for prevention or treatment of negative nitrogen balance
Treatment of uremic patients undergoing dialysis who require essential amino acid supplementation,Nutritional support in patients with renal insufficiency or failure where nonessential nitrogen sources are contraindicated
Intravenous administration. The dose is individualized based on patient's metabolic requirements, clinical condition, and tolerance. Typical adult dose: 1 to 2 L per day of CLINIMIX E 2.75/5 with electrolytes in 5% dextrose with calcium, infused at a rate not exceeding 4 mg/kg/min of dextrose (or as tolerated).
Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
Not applicable as a single entity; components have independent half-lives. Amino acids have plasma half-lives of minutes to hours depending on individual amino acid and metabolic state. Dextrose has an elimination half-life of 1.5-2.5 hours in normal glucose tolerance. Electrolytes are not described by half-life due to homeostatic regulation.
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
Amino acids are metabolized in the liver and peripheral tissues via transamination, deamination, and urea cycle. Dextrose is metabolized via glycolysis and the Krebs cycle. Electrolytes are distributed and excreted primarily by the kidneys. Calcium metabolism is regulated by the kidneys, bones, and gastrointestinal tract.
Amino acids are metabolized via transamination, deamination, and incorporation into proteins. Hepatic and renal pathways involved in nitrogen disposal and urea cycle.
CLINIMIX E 2.75/5 is a parenteral nutrition solution; components are eliminated via normal metabolic pathways. Amino acids undergo deamination and oxidation, with nitrogen excreted renally as urea (80-90%). Glucose is metabolized to CO2 and water, excreted via lungs and kidneys. Electrolytes are excreted renally in proportion to intake and homeostatic regulation.
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Amino acids are minimally protein bound (<10%); dextrose is not protein bound; electrolytes such as calcium and magnesium are partially bound to albumin (calcium ~50% bound, magnesium ~30% bound). Multivalent cations bind to various plasma proteins.
Minimal (<10%) for most amino acids; not significantly protein-bound.
Not a single value. Amino acids distribute into total body water (~0.6 L/kg); dextrose distributes mainly into extracellular fluid (~0.2 L/kg) but is rapidly taken up by cells; electrolytes distribute according to their physiological compartments (e.g., sodium extracellular, potassium intracellular).
Approximately 0.2-0.4 L/kg total body water; reflects distribution primarily into extracellular fluid.
Intravenous administration yields 100% bioavailability. Not administered via other routes.
Intravenous: 100%.
GFR > 50 m L/min: No adjustment needed. GFR 30-50 m L/min: Reduce volume by 50% or use a lower concentration of amino acids and electrolytes, monitor serum potassium, phosphate, and magnesium. GFR < 30 m L/min: Contraindicated or use extreme caution with dose reduction and close monitoring of electrolytes and fluid balance.
For GFR < 30 m L/min: reduce dose to 0.5-0.8 g/kg/day; for GFR < 15 m L/min: 0.3-0.5 g/kg/day; avoid if severe untreated uremia.
Child-Pugh A: No adjustment needed. Child-Pugh B: Reduce amino acid dose by 50% and monitor for hyperammonemia. Child-Pugh C: Use with caution; avoid if severe hepatic encephalopathy; may require reduction or use of specialized amino acid formulations.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated due to risk of hepatic encephalopathy.
Weight-based dosing: Initiate at 0.5-1 g/kg/day of amino acids, increasing gradually to a target of 2-3 g/kg/day. Dextrose: start at 5-10 mg/kg/min, increase as tolerated up to 12-15 mg/kg/min. Electrolytes: adjust based on serum levels. Total volume: typically 100-150 m L/kg/day for infants, adjusted for clinical condition.
Infants and children: 1-2 g/kg/day as continuous infusion; neonates: 0.5-1 g/kg/day, titrated to metabolic response.
Elderly patients may have reduced renal and hepatic function. Start at lower end of dosing range (e.g., 1 L/day or less) and titrate slowly. Monitor fluid balance, electrolytes, and renal function closely. Avoid rapid infusion to prevent fluid overload.
Start at 0.6-0.8 g/kg/day; monitor renal function and protein tolerance; adjust for comorbidities like renal impairment or heart failure.
This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions which contain aluminum.
Not for intravenous infusion. For oral or enteral use only. Do not administer parenterally.
Monitoring: serum electrolytes, blood glucose, fluid balance, liver function, renal function, and acid-base status,Risk of hyperglycemia, hyperosmolar state, and metabolic acidosis,Risk of aluminum toxicity, especially in renal impairment and premature infants,Do not administer unless solution is clear and container is undamaged,Use with caution in patients with heart failure, renal failure, or hepatic impairment
Monitor serum electrolytes, BUN, and ammonia levels; risk of hyperammonemia in hepatic impairment,Use with caution in patients with metabolic acidosis or fluid overload,May cause gastrointestinal intolerance; adjust rate of administration
Hypersensitivity to any component,Severe hyperglycemia (e.g., diabetic coma),Drug-induced lactic acidosis,Galactosemia (for dextrose-containing solutions),Severe electrolyte imbalances (unless corrected)
Hypersensitivity to any component,Phenylketonuria (contains phenylalanine),Severe hepatic failure with hyperammonemia
No direct food interactions, but parenteral nutrition may affect nutritional status. Enteral intake should be coordinated with the clinical team. Avoid concurrent administration of other IV solutions without compatibility check.
No specific food interactions. Patients should follow prescribed dietary protein restrictions if indicated (e.g., in hepatic encephalopathy). Avoid alcohol as it may worsen liver function.
No known teratogenic risk; components (amino acids, dextrose, electrolytes) are physiological and essential for fetal development. No trimester-specific risks identified with standard use.
Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status directly impacts fetal outcomes.
Considered compatible with breastfeeding; components are normal constituents of human milk. M/P ratio not applicable as mixture of nutrients; no adverse effects reported.
No data available on milk concentrations. Essential amino acids are normal components of breast milk. Use with caution; benefits likely outweigh risks in malnourished mothers.
No specific dose adjustments required; standard dosing per maternal weight and nutritional needs. Monitor for gestational changes in fluid and electrolyte requirements.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics. Monitor clinical response and consider dose adjustments based on metabolic demands; no specific dose adjustment guidelines available.
CLINIMIX E 2.75/5 with electrolytes in dextrose 5% and calcium is a parenteral nutrition solution for IV use only. Monitor serum electrolytes, glucose, and renal function closely; do not administer simultaneously with blood products. Check for precipitate formation; use a dedicated line. Contains sulfite-free formulation for patients with sulfite sensitivity.
Monitor serum ammonia levels in patients with hepatic impairment as essential amino acids may exacerbate hyperammonemia. Use with caution in fluid-restricted patients due to high volume load. Ensure adequate non-protein calories to promote protein synthesis and prevent amino acid catabolism. Do not administer simultaneously with blood products via same IV line.
This medication is given through a vein (IV) and should be administered only by a healthcare professional.,Report any signs of infection at the IV site, such as redness, swelling, or pain.,Inform your healthcare provider of any history of allergies, especially to sulfites.,This solution provides complete nutrition, including amino acids, electrolytes, and dextrose. You may still eat or drink if permitted by your doctor.,Blood tests will be performed regularly to monitor your electrolyte levels, blood sugar, and kidney function.
This solution provides essential amino acids to support protein synthesis when you cannot eat enough protein.,It is given intravenously; report any burning, pain, or swelling at the IV site.,Your blood may be monitored for ammonia and electrolyte levels during treatment.,Inform your healthcare provider if you have liver disease, diabetes, or fluid restrictions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, answered by our medical review team.
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by CLINIMIX E 2.75/5 is a combination of amino acids, electrolytes, and dextrose used for parenteral nutrition. The amino acids provide substrates for protein synthesis, dextrose supplies caloric energy, and electrolytes maintain acid-base and fluid balance. Calcium is included for bone health and neuromuscular function.. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is a Parenteral Nutrition Solution that works by Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER is: Intravenous administration. The dose is individualized based on patient's metabolic requirements, clinical condition, and tolerance. Typical adult dose: 1 to 2 L per day of CLINIMIX E 2.75/5 with electrolytes in 5% dextrose with calcium, infused at a rate not exceeding 4 mg/kg/min of dextrose (or as tolerated).. The standard adult dose of AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is: Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. No known teratogenic risk; components (amino acids, dextrose, electrolytes) are physiological and essential for fetal development. No trimester-specific risks identified with stand. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is classified as Category C. Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status dire. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.